| 1 |
33588740 | Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance. | 2022 |
2 |
| 2 |
33556804 | A Cost-Effectiveness Analysis of Neuraminidase Inhibitors for Influenza Virus Infections in an Adult-Outpatient Setting in Japan. | 2021 May |
1 |
| 3 |
31368872 | Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza. | 2020 |
1 |
| 4 |
31955521 | Antigenic variants of influenza B viruses isolated in Japan during the 2017-2018 and 2018-2019 influenza seasons. | 2020 May |
1 |
| 5 |
32130243 | Epidemic of influenza A(H1N1)pdm09 analyzed by full genome sequences and the first case of oseltamivir-resistant strain in Myanmar 2017. | 2020 |
2 |
| 6 |
32394467 | A global treatments for coronaviruses including COVID-19. | 2020 Dec |
1 |
| 7 |
32631240 | Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report. | 2020 Jul 6 |
2 |
| 8 |
32631440 | Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea. | 2020 Jul 6 |
1 |
| 9 |
32768954 | Pharmacokinetic behavior of peramivir in the plasma and lungs of rats after trans-nasal aerosol inhalation and intravenous injection. | 2020 Sep |
1 |
| 10 |
30526812 | Comparison of the effects of peramivir and oseltamivir on the rise in platelet count in patients with or without proven influenza
. | 2019 Mar |
1 |
| 11 |
31323237 | The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors. | 2019 Oct |
1 |
| 12 |
31645133 | Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach. | 2019 Dec |
1 |
| 13 |
31692637 | Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents. | 2019 |
1 |
| 14 |
31702775 | Key amino acid residues of neuraminidase involved in influenza A virus entry. | 2019 Aug 1 |
1 |
| 15 |
29903413 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. | 2018 Oct 15 |
1 |
| 16 |
30060497 | Preparation and Evaluation of Oseltamivir Molecularly Imprinted Polymer Silica Gel as Liquid Chromatography Stationary Phase. | 2018 Jul 27 |
1 |
| 17 |
30196350 | Peramivir: A Review in Uncomplicated Influenza. | 2018 Sep |
1 |
| 18 |
32104429 | PEPT1-mediated prodrug strategy for oral delivery of peramivir. | 2018 Nov |
2 |
| 19 |
26542650 | Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus. | 2017 Oct |
1 |
| 20 |
28337082 | Pharmacokinetics of Peramivir in an Adolescent Patient Receiving Continuous Venovenous Hemodiafiltration. | 2017 Jan-Feb |
2 |
| 21 |
27497712 | Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors. | 2016 Oct |
2 |
| 22 |
27578993 | Peramivir injection in the treatment of acute influenza: a review of the literature. | 2016 |
1 |
| 23 |
27845731 | Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. | 2016 Nov 11 |
2 |
| 24 |
24612842 | Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. | 2015 Apr |
1 |
| 25 |
25523716 | Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation. | 2015 Mar |
2 |
| 26 |
25629811 | Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. | 2015 Feb 2 |
2 |
| 27 |
26153242 | Peramivir: an intravenous neuraminidase inhibitor. | 2015 |
2 |
| 28 |
26282420 | Population pharmacokinetics of peramivir in healthy volunteers and influenza patients. | 2015 Nov |
1 |
| 29 |
24001233 | Drugs against avian influenza a virus: design of novel sulfonate inhibitors of neuraminidase N1. | 2014 |
1 |
| 30 |
24560563 | In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. | 2014 Feb |
2 |
| 31 |
25131292 | Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation. | 2014 Nov |
2 |
| 32 |
25318805 | Severe immune thrombocytopenia possibly elicited by the anti-influenza viral agent peramivir. | 2014 |
1 |
| 33 |
25345428 | Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. | 2014 Dec |
1 |
| 34 |
25368514 | Safety and efficacy of peramivir for influenza treatment. | 2014 |
2 |
| 35 |
23422872 | Balancing societal needs and regulatory certainty: the case study of peramivir in Japan. | 2013 Apr |
1 |
| 36 |
23860768 | Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. | 2013 Jul 16 |
1 |
| 37 |
24821568 | Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. | 2013 |
1 |
| 38 |
21960669 | Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. | 2012 Sep |
1 |
| 39 |
22024821 | Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. | 2012 Jan |
1 |
| 40 |
22339187 | Peramivir for the treatment of influenza. | 2012 Feb |
1 |
| 41 |
22768265 | Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. | 2012 |
1 |
| 42 |
21208927 | Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. | 2011 Feb 1 |
1 |
| 43 |
21825298 | Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. | 2011 Nov |
1 |
| 44 |
21858186 | Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. | 2011 |
3 |
| 45 |
22001088 | The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase. | 2011 Dec 1 |
2 |
| 46 |
22099093 | Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. | 2011 Nov |
1 |
| 47 |
22116989 | Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. | 2011 Dec |
1 |
| 48 |
20334616 | Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy. | 2010 Jun |
1 |
| 49 |
20695427 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. | 2010 Sep 9 |
3 |
| 50 |
20959843 | The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. | 2010 Nov |
1 |